On World Colorectal Cancer Day, we want to shed light on the importance of early detection and treatment of this global health challenge. Colorectal cancer is the third most common cancer diagnosis and the second leading cause of cancer deaths worldwide.
Aniling is determined to make a significant impact by improving the diagnosis and treatment of this disease. Our advanced GEUS technology has enabled us to develop two innovative products: a liquid biopsy test (GEUS-LB) and a tissue biopsy test (GEUS-CRC), which promise accurate and early detection.
As published early this week, we are also partnering with ICO and IGTP to create a personalized theragnostic tool for the management of colorectal cancer, which has been recognized and awarded by the Spanish State Research Agency.
At Aniling, we are committed to reducing the impact of this disease on patients’ lives. Join us against colorectal cancer!